[ET Net News Agency, 7 April 2021] Goldman Sachs lowered its target price for Venus
Medtech (02500) to HK$70.77 from HK$71.6 and maintained its "buy" rating.
The research house said it maintains the buy rating with a fine-tuned 12-m risk-adjusted
DCF-based TP of HK$70.77 to factor in (1) the updated financials; (2) higher TAVR volume
from aortic regurgitation by 2031E; (3) rollover of DCF model to 2031E (from 2030E). The
DCF assumes (1) a 10% discount rate; (2) a 3% terminal growth rate; and (3) probability of
success (PoS) based on industry average success rates in different stages and adjustments
based on available clinical data - assumptions unchanged. (RC)